🔍

Bharat Parenterals Ltd (541096)

📊 BSE: 541096 🏢 Pharmaceuticals 📢 Latest filing: 13 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Bharat Parenterals' revenue was ₹93.7 Cr (-19.2% year on year, -5.9% on the previous quarter), and net profit ₹-3.6 Cr (a bigger loss than a year earlier); the operating margin was 9.1%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹93.7	-19.2%	-5.9%
Operating profit	₹8.5	-38.1%	from loss
Net profit	₹-3.6	loss widened	loss narrowed
EPS (₹)	-5.17	to loss	loss narrowed
Operating margin	9.1%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Bharat Parenterals Appoints Crisil for >₹100 Cr Preferential Issue Following BSE Directive

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 13 Oct 2026, 03:25 PM

Bharat Parenterals Ltd has issued a corrigendum to its October 23, 2026 EGM notice following directions from BSE Limited. Because the proposed preferential issue size exceeds ₹100 crore, the company is mandated under SEBI ICDR Regulation 162A to appoint a monitoring agency. Consequently, Crisil Ratings Limited has been appointed to oversee the utilization of proceeds. A fundraise exceeding ₹100 crore represents over 6% of the company's current market cap of ₹1,570 crore and nearly 31% of its TTM revenue of ₹323 crore.

Proposed preferential issue size exceeds INR 100,00,00,000/- (₹100 crore)
BSE directed additional disclosures on the appointment of a Monitoring Agency under Regulation 162A
Crisil Ratings Limited appointed as the SEBI-registered Monitoring Agency
Extraordinary General Meeting (EGM) scheduled for October 23, 2026 at 11:30 AM via VC/OAVM

💡 Track the outcome of shareholder voting at the EGM on October 23, 2026, and subsequent disclosures regarding exact issue pricing, dilution, and specific deployment plans.

Bharat Parenterals to raise ₹139 Cr via preferential issue at ₹1,522.85/share; calls EGM on Oct 23

🟢 POSITIVE ⭐ 9/10

FUNDRAISE 📅 01 Oct 2026, 05:39 PM

Bharat Parenterals has issued an EGM notice to approve a preferential equity issue of up to 9,12,759 shares at ₹1,522.85 per share, raising ₹138.99 Cr. The fundraise is targeted at marquee institutional investors including WhiteOak Capital funds, Aurum Rising India Fund, and Ashoka India Equity Investment Trust. The fundraise represents approximately 8.9% of the company's current market cap of ₹1,570 Cr and ~43% of TTM revenue. Following the allotment, promoter shareholding will dilute from 67.20% to 59.35%.

Proposed issue of 9,12,759 equity shares at an issue price of ₹1,522.85 per share
Total consideration to be raised aggregates to ₹138,99,95,043.15 (approx. ₹139 Cr)
Key allottees include WhiteOak Capital entities (over ₹78 Cr) and Aurum Rising India Fund (₹25 Cr)
Promoter holding will decrease from 67.20% to 59.35% post-allotment
EGM scheduled for October 23, 2026, with remote e-voting from October 20 to October 22, 2026

💡 Track shareholder voting results at the EGM on October 23, 2026, and monitor subsequent disclosures regarding the specific end-use allocation of the ₹139 Cr proceeds.

Bharat Parenterals to raise ₹139 Cr via preferential allotment at ₹1522.85/share

🟢 POSITIVE ⭐ 9/10

FUNDRAISE 📅 29 Sep 2026, 04:22 PM

Bharat Parenterals has approved a preferential allotment of up to 9,12,759 equity shares at ₹1522.85 per share to raise ₹138.99 crore. This fundraise represents ~8.9% of the current market capitalization and ~43% of TTM revenue (₹323 crore). The proceeds are earmarked for investments in or loans to subsidiaries for developing existing and new projects. Institutional investors, including several WhiteOak Capital entities, account for a substantial portion of the proposed allotment. An Extraordinary General Meeting (EGM) has been scheduled for October 23, 2026, to seek shareholder approval.

Board approved issuance of 9,12,759 equity shares at ₹1522.85 per share
Aggregate consideration to be raised is ₹138,99,95,043.15 (~₹139 crore)
Proceeds intended for investments/loans to subsidiaries for project development
Key institutional allottees include WhiteOak Capital and Aurum Rising India Fund across 15 investors
Extraordinary General Meeting scheduled for October 23, 2026

💡 Monitor the voting outcome of the EGM on October 23, 2026, and look for subsequent disclosures detailing the specific subsidiary projects and timeline of capital deployment.

Bharat Parenterals Schedules Board Meeting on Sep 29, 2026 to Consider Preferential Issue

🔵 WATCH ⭐ 4/10

BOARD_MEETING 📅 24 Sep 2026, 02:28 PM

Bharat Parenterals Ltd has announced a Board of Directors meeting scheduled for September 29, 2026, to evaluate and consider a proposal for raising funds via a preferential issue of equity shares or other eligible securities. The company has a current market capitalization of ₹1,570 crore and reported a TTM net loss of ₹30 crore on TTM revenue of ₹323 crore. The quantitative details regarding the issue size, pricing, and specific investor allottees have not yet been disclosed. Trading window closure for designated persons is effective immediately until 48 hours post-meeting conclusion.

Board meeting scheduled on Tuesday, September 29, 2026
Agenda includes evaluating and approving fundraise via Preferential Issue
Trading window closed effective September 24, 2026 until 48 hours post-meeting
Issue quantum and proposed allottees currently not disclosed

💡 Track the outcome of the September 29 board meeting for details on the issue size, dilution percentage, pricing formula, and whether funds are raised from promoters or strategic institutional investors.

Bharat Parenterals Dispatches FY26 Annual Report Intimation; AGM Set for Sept 19, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 05:17 PM

Bharat Parenterals Limited has informed the exchanges regarding the dispatch of letters to shareholders without registered email addresses, providing instructions to access the Annual Report for FY 2025-26. The company has scheduled its 33rd Annual General Meeting (AGM) for Saturday, September 19, 2026, at 11:00 AM IST via Video Conferencing. The cut-off date for determining shareholder voting eligibility is Saturday, September 12, 2026.

33rd Annual General Meeting scheduled for September 19, 2026, at 11:00 AM IST
Cut-off date for electronic voting fixed as September 12, 2026
Annual Report for FY 2025-26 and AGM notice made accessible via company website
Dispatch completed under Regulation 36(1)(b) of SEBI LODR Regulations

💡 Shareholders seeking to vote at the 33rd AGM should verify shareholding status before the cut-off date of September 12, 2026, and update KYC/email details with their RTA/DP.

Bharat Parenterals Sets September 12, 2026 as Record Date for FY26 Dividend

🟡 NEUTRAL ⭐ 4/10

DIVIDEND 📅 27 Aug 2026, 05:10 PM

Bharat Parenterals Ltd has fixed Saturday, September 12, 2026, as the record date to determine shareholder eligibility for the final dividend for FY 2025-26. The dividend payout is subject to shareholder approval at the Annual General Meeting scheduled for September 19, 2026. The exact dividend amount per share was not disclosed in this filing.

Record date fixed as Saturday, September 12, 2026
Purpose is determining member entitlement for FY 2025-26 dividend
AGM scheduled for September 19, 2026 to seek shareholder approval

💡 Track the upcoming AGM on September 19, 2026 for dividend approval and check the ex-dividend date prior to September 12, 2026.

Bharat Parenterals Releases FY26 Annual Report; Recommends ₹1/Share Dividend, AGM on Sept 19

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Aug 2026, 05:05 PM

Bharat Parenterals Limited has released its Annual Report for FY 2025-26 and scheduled its 33rd Annual General Meeting (AGM) for September 19, 2026. On a consolidated basis, FY26 revenue reached ₹354.98 Cr with a reduced net loss of ₹27.31 Cr compared to a loss of ₹43.68 Cr in FY25. On a standalone basis, operational turnover stood at ₹246.57 Cr with a net profit after tax of ₹16.02 Cr. The Board has recommended a final dividend of ₹1.00 per equity share (face value ₹10) for FY26.

Consolidated FY26 revenue was ₹354.98 Cr, while consolidated net loss narrowed to ₹27.31 Cr (vs loss of ₹43.68 Cr in FY25)
Standalone operational turnover reported at ₹246.57 Cr with a standalone net profit of ₹16.02 Cr (EPS ₹23.24)
Recommended final dividend of ₹1.00 per equity share of ₹10 face value for FY26
33rd Annual General Meeting scheduled for Saturday, September 19, 2026 via VC/OAVM
Achieved 48 registrations in FY26 with 214 dossiers active across 40+ export markets

💡 Track shareholder approvals and management commentary during the AGM on September 19, 2026, alongside upcoming Q2 FY27 earnings for signs of sustained operational turnaround.

Bharat Parenterals Convenes 33rd AGM on Sep 19, 2026; Proposes ₹1/Share Final Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Aug 2026, 03:41 PM

Bharat Parenterals Limited has issued the notice for its 33rd Annual General Meeting (AGM) scheduled for Saturday, September 19, 2026, via Video Conferencing. Key agenda items include the approval of audited financial statements for FY26 and the declaration of a final dividend of ₹1.00 per share. The company is also seeking shareholder approval for the re-appointment of Mr. Hemang Shah as Executive Director for a 5-year tenure with proposed annual remuneration of ₹36,00,000. Remote e-voting runs from September 16 to September 18, 2026, with a cut-off date of September 12, 2026.

33rd AGM scheduled for September 19, 2026, at 11:00 AM IST via Video Conferencing
Final dividend of ₹1.00 per share proposed for FY26 subject to shareholder approval
Proposed re-appointment of Executive Director Hemang Shah for 5 years (July 2, 2026 to July 1, 2031) at ₹36,00,000 p.a. remuneration
Cut-off date for remote e-voting set as September 12, 2026; voting window active from September 16 to September 18, 2026
Approval sought for cost auditor remuneration of ₹75,000 plus taxes for FY27

💡 Eligible shareholders can participate in remote e-voting between September 16 and September 18, 2026, ahead of the AGM on September 19, 2026.

Bharat Parenterals Permitted to Trade on NSE Under Symbol BPLPHARMA from August 17, 2026

🟢 POSITIVE ⭐ 3/10

ROUTINE 📅 20 Aug 2026, 12:38 PM

Bharat Parenterals Limited announced that its 6,891,963 equity shares of face value Rs 10 each have been admitted to dealings and permitted to trade on the Capital Market Segment of the National Stock Exchange (NSE) effective August 17, 2026. Trading will take place under the symbol BPLPHARMA with a market lot of 1. This comes in addition to the company's existing listing on the BSE (Scrip Code: 541096).

NSE admitted 6,891,963 equity shares to trade under symbol BPLPHARMA
Trading effective on NSE Capital Market Segment from August 17, 2026
Shares have face value of Rs 10 with market lot of 1
Trading permitted pursuant to NSE Circular No. NSE/CML/75748 dated August 14, 2026

💡 Track trading volumes and liquidity improvements on NSE alongside upcoming quarterly financial performance.

₹300 Cr Capex: Bharat Parenterals Doubles Investment for Biologics & Oncology Facility

🟢 POSITIVE ⭐ 9/10

EXPANSION 📅 11 Aug 2026, 03:39 PM

Bharat Parenterals' subsidiary, Varenyam Biolifesciences, has revised its Phase 1 capital expenditure for the Savli facility to ₹300 crore, doubling the previous estimate of ₹150 crore. The facility is being upgraded to include biologics and biosimilar CDMO capabilities alongside its existing oncology focus. This investment is highly material, representing approximately 87% of the company's TTM revenue and 93% of its net worth. The project targets high-regulated markets including the US and EU, with a targeted completion date of Q2 2028.

Revised Phase 1 capital expenditure of ₹300 crore, up from the previously planned ₹150 crore.
Facility upgrade to include biologics and biosimilar CDMO services for US, EU, and SRA markets.
Targeted completion date for the Savli manufacturing facility is Q2 2028.
Regulatory approvals to be pursued include USFDA, EU-GMP, and ANVISA.
Strategic shift to address the USD 24-27 billion global biologics CDMO market.

💡 Monitor the company's funding strategy for this ₹300 crore outlay given its current negative PAT and ROCE. Investors should track construction milestones and the eventual USFDA/EU-GMP inspection timeline toward 2028.

Bharat Parenterals to Meet Investors on August 13, 2026, Hosted by Emkay Global

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Aug 2026, 04:39 PM

Bharat Parenterals Ltd has scheduled a physical analyst and investor meeting in Mumbai on August 13, 2026, starting at 10:00 AM. The meeting is organized by Emkay Global Financial Services Ltd and will involve both one-on-one and group interactions. This engagement occurs as the company navigates a challenging financial period, having reported a TTM net loss of ‹27 crore on revenue of ‹345 crore. No unpublished price-sensitive information is expected to be disclosed during the session.

Physical meeting scheduled for August 13, 2026, in Mumbai.
Interaction hosted by Emkay Global Financial Services Ltd.
Company reported a TTM net loss of ‹27 crore as of the latest financial data.
Market capitalization stands at ‹3,160 crore with a high Price-to-Book ratio of 9.8.
Promoter holding remains stable at 67.2% as of June 2026.

💡 Investors should monitor the company's website for any post-meeting presentations or transcripts to understand management's plan for returning to profitability given the current negative ROCE of -2.0%.

₹93.7 Cr Revenue: Bharat Parenterals Reports Q1 FY27 Loss Amid Subsidiary Scale-up

🔵 WATCH ⭐ 7/10

EARNINGS 📅 05 Aug 2026, 06:03 PM

Bharat Parenterals reported a 19.2% YoY decline in consolidated revenue to ₹93.7 Cr for Q1 FY27, primarily due to a high base in the standalone business following the completion of a large ₹210 Cr institutional order. Despite the revenue drop, gross margins improved significantly by approximately 1,000 bps to 50.6% due to a better product mix. The company posted a consolidated net loss of ₹3.6 Cr, largely attributed to a ₹10.4 Cr loss at its Innoxel subsidiary, which is currently building capacity ahead of contracted revenue. Notably, subsidiaries Innoxel and Varenyam now contribute 46% of consolidated revenue, up from 21% a year ago.

Consolidated revenue declined 19.2% YoY to ₹93.7 Cr, representing ~27% of TTM revenue.
Gross margin expanded by 1,000 bps to 50.6%, keeping gross profit flat at ₹47.4 Cr despite lower volumes.
Innoxel subsidiary revenue surged 165% YoY to ₹21.4 Cr following USFDA EIR receipt.
Varenyam Healthcare reached a record revenue of ₹25.1 Cr with a 12.4% EBITDA margin.
Operating expenses rose 16.5% YoY to ₹38.9 Cr as the company builds ahead of forward revenue contracts.

💡 Monitor the EBITDA break-even timeline for the Innoxel subsidiary and the sustainability of the 50%+ gross margins as the business shifts from low-margin tenders to branded and CDMO sales.

Bharat Parenterals Re-appoints Hemang Shah as Executive Director for 5-Year Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 05 Aug 2026, 05:57 PM

Bharat Parenterals has approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term effective from July 02, 2026, to July 01, 2031. Mr. Shah brings over 30 years of experience and has been associated with the company for more than two decades. The re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. This leadership continuity comes as the company navigates a challenging financial period, reporting a TTM loss of ‡27 crore on revenue of ‡345 crore.

Re-appointment of Mr. Hemang Shah for a 5-year term starting July 02, 2026
Mr. Shah has over 30 years of professional experience in the industry
Associated with the company for more than 20 years (two decades)
Company reported TTM revenue of ‡345 crore with a net loss of ‡27 crore
Promoter holding remains stable at 67.2% as of June 2026

💡 Investors should monitor the upcoming Annual General Meeting for shareholder approval and look for management commentary on strategies to improve the current negative ROCE of -2.0%.

Bharat Parenterals Q1 Results: Revenue Drops 19% YoY to ₹93.74 Cr, Returns to Profitability

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 05 Aug 2026, 05:49 PM

Bharat Parenterals reported a consolidated revenue of ₹93.74 cr for Q1 FY27, marking a 19.2% decline from ₹116.00 cr in the same quarter last year. Despite the revenue drop, the company returned to a standalone net profit of ₹3.66 cr, a significant sequential improvement from the ₹8.16 cr loss in the preceding March quarter, though down 63.4% YoY. Consolidated EBITDA margins (excluding other income) contracted to 9.10% from 11.88% YoY. The board also approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term.

Consolidated revenue from operations declined 19.2% YoY to ₹93.74 cr from ₹116.00 cr.
Standalone net profit stood at ₹3.66 cr, down 63.4% compared to ₹10.00 cr in Q1 FY26.
Consolidated EBITDA (excluding other income) fell to ₹8.53 cr from ₹13.78 cr in the year-ago period.
Consolidated EBITDA margin (excluding other income) compressed by 278 bps to 9.10%.
Re-appointment of Mr. Hemang Shah as Executive Director approved for a 5-year term starting August 2026.

💡 Investors should monitor if the company can sustain this return to profitability after a loss-making FY26, and watch for management commentary regarding the sharp 19% YoY revenue contraction.

Bharat Parenterals Q1 FY27: Standalone Net Profit at ₹3.66 Cr, Revenue Declines 19% YoY

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 05 Aug 2026, 05:40 PM

Bharat Parenterals reported a consolidated revenue of ₹93.74 Cr for Q1 FY27, representing a 19.2% decline from ₹116.00 Cr in the same quarter last year. On a standalone basis, the company achieved a net profit of ₹3.66 Cr, a notable recovery from the ₹8.16 Cr loss reported in the preceding March 2026 quarter. Consolidated EBITDA margins (including other income) contracted to 10.29% from 12.79% YoY. The board also approved the re-appointment of Mr. Hemang Shah as Executive Director for a five-year term.

Consolidated Revenue from operations stood at ₹93.74 Cr, down from ₹116.00 Cr in Q1 FY26.
Standalone Net Profit reached ₹3.66 Cr, reversing a loss of ₹8.16 Cr in the previous quarter.
Consolidated EBITDA (including other income) was ₹9.65 Cr with a margin of 10.29%.
Standalone Finance Costs decreased to ₹0.69 Cr from ₹1.42 Cr in the year-ago period.
The 33rd Annual General Meeting is scheduled for September 19, 2026.

💡 Monitor the company's ability to sustain standalone profitability and reverse the YoY revenue decline in upcoming quarters. Watch for management commentary during the AGM on September 19 regarding the strategy to improve consolidated margins.

View All 541096 Announcements on Live Market Tracking →